Globalpharma exhibits new generics brands at DUPHAT 2013

Held under the patronage of His Highness Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance, UAE and President of Dubai Health Authority (DHA), the 19th edition of DUPHAT is running from 10 - 12 March.

Globalpharma is using the opportunity to showcase its branded-generics that are manufactured in accordance with international quality, safety and production standards.

Branded-generics are drugs that are scientifically formulated using the same core chemical ingredients found in the original medicine that is off-patent.

The company's unique generics line-up includes Gloclav, Atorlip, Emifenac DT, Emilok, as well as recently launched products such as Emivanz and Emipride.

Jamil Akhtar, General Manager, Globalpharma, said, "The local health ministry is continuously promoting the need to develop the generics sector in the UAE, in order to ensure the timely availability of medication at affordable prices. Globalpharma is conscious of the demand, and has gradually increased its offering of generics through a well-developed infrastructure and long-standing local market expertise."

"DUPHAT is a key event that highlights the progress of the regional pharma industry, and addresses the concerns and needs of local pharmaceutical manufacturers. The event has given Globalpharma a chance to explore new opportunities and forge synergies with international pharmaceutical companies looking to enter the Middle East market. We congratulate the organisers and the DHA on yet another successful edition of the conference, and look forward to continued collaboration as part of our growth strategy," he added.

Globalpharma manufactures and markets pharmaceutical products in more than 20 countries across the Middle East, Africa and Far East. The company produces a diverse range of medicines including antibiotics, analgesics/NSAIDs, anti-ulcerant, respiratory products, nutritional supplements, as well medication for chronic conditions such as cardiovascular disease and diabetes.

Globalpharma started its commercial operation in 2003 and within a short span of time emerged as a quality-centric and reliable player in the MEA pharmaceutical market.